Aspire Private Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Aspire Private Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20	Closed	-$310	–	691
2024 Q2	$310	Hold	20	–	–	﹤0.01%	645
2024 Q1	$319	Hold	20	–	–	﹤0.01%	672
2023 Q4	$336	Hold	20	–	–	﹤0.01%	658
2023 Q3	$233	Hold	20	–	–	﹤0.01%	667
2023 Q2	$269	Hold	20	–	–	﹤0.01%	632
2023 Q1	$332	Hold	20	–	–	﹤0.01%	613
2022 Q4	$372	Hold	20	–	–	﹤0.01%	607
2022 Q3	$0	Buy	+20	New	+$237	﹤0.01%	618

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Aspire Private Capital's CPRX Position: Q3 2024 in Review

Aspire Private Capital sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 20 shares — an estimated $310 sold.

Aspire Private Capital first reported a position in CPRX in Q3 2022 and held it in 8 quarters. The position peaked at $372 in Q4 2022. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

Aspire Private Capital reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Aspire Private Capital sold 20 Catalyst Pharmaceutical shares in Q3 2024, an estimated $310.
Aspire Private Capital first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 8 quarters.
Aspire Private Capital's Catalyst Pharmaceutical position peaked at $372 in Q4 2022.
316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Aspire Private Capital's 13F filing for Q3 2024, filed 25 Oct 2024.